Machalińska Anna, Zakrzewska Aleksandra, Safranow Krzysztof, Wiszniewska Barbara, Machaliński Bogusław
Department of Histology and Embryology, Pomeranian Medical University, Al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland; Department of Ophthalmology, Pomeranian Medical University, Al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland.
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland.
J Ophthalmol. 2016;2016:7526120. doi: 10.1155/2016/7526120. Epub 2016 Nov 14.
. The aim of this study was to investigate the relationships between MGL and ocular symptoms, several systemic conditions, and key markers of ocular surface health. . We included into the study 91 healthy volunteers between the ages of 20 and 77 years. We analyzed meibomian gland morphology, function, and lid margin alterations. We correlated our findings with self-reported ocular symptoms, systemic medical history, lifestyle factors, and tear film abnormalities. . We observed that a high ocular surface disease index, a history of either chalazion or hordeolum, experience of puffy eyelids upon waking, and foreign body sensation all appeared to be predictors of an abnormal meiboscore after adjusting for age and sex ( = 0.0007; = 0.001; = 0.02; = 0.001, resp.). Multivariate logistic regression model including age and sex showed that there were three independent predictors of abnormal meiboscore: older age (OR = 1.03, 95% CI = 1.01-1.04 per year, = 0.006), postmenopausal hormone therapy (OR = 4.98, 95% CI = 1.52-16.30, = 0.007), and the use of antiallergy drugs (OR = 5.85, 95% CI = 2.18-15.72, = 0.0004). . Our findings extend current knowledge on the pathophysiology of MGL.
本研究的目的是调查睑板腺脂质（MGL）与眼部症状、几种全身状况以及眼表健康关键标志物之间的关系。我们纳入了91名年龄在20至77岁之间的健康志愿者进行研究。我们分析了睑板腺的形态、功能和睑缘改变。我们将研究结果与自我报告的眼部症状、全身病史、生活方式因素和泪膜异常进行了关联分析。我们观察到，在调整年龄和性别后，高眼表疾病指数、睑板腺囊肿或麦粒肿病史、醒来时眼睑肿胀的经历以及异物感似乎均为睑板腺评分异常的预测因素（分别为P = 0.0007；P = 0.001；P = 0.02；P = 0.001）。包含年龄和性别的多因素逻辑回归模型显示，睑板腺评分异常有三个独立预测因素：年龄较大（比值比[OR] = 1.03，95%置信区间[CI] = 1.01 - 1.04/年，P = 0.006）、绝经后激素治疗（OR = 4.98，95% CI = 1.52 - 16.30，P = 0.007）以及使用抗过敏药物（OR = 5.85，95% CI = 2.18 - 15.72，P = 0.0004）。我们的研究结果扩展了目前关于睑板腺脂质病理生理学的知识。
